Moderna Expands mRNA Capability Through $85m OriCiro Acquisition
Executive Summary
Moderna has made its first-ever acquisition with the $85m purchase of OriCiro Genomics, a Japanese bioventure with DNA synthesis and amplification technology. The deal is expected to contribute to Moderna’s capabilities in both manufacturing and R&D.
You may also be interested in...
Bancel Takes Commercial Reins As Moderna Braces For 2024 Downturn
Moderna is saying goodbye to its second chief commercial officer in three years and CEO Stéphane Bancel will direct operations personally – including the firm’s anticipated RSV vaccine launch in 2024
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.